But with this work, the EPFL researchers were able to shed some more light on it by determining how the drug compounds affect gamma secretase
and its cutting activity.
Our drug candidates selectively modulate gamma secretase
, the enzyme generating the neurotoxic peptides that form amyloid beta plaques, the signature of this debilitating disease.
Due to the complexity of the Notch signalling that leads up to the cleavage by gamma secretase
, it is proposed that Notch inhibition can be achieved on multiple levels.
believed to block the activity of gamma secretase
, an enzyme that is
as targets for the treatment of Alzheimer's disease: the prospects.
Other research has shown that statins (cholesterol-lowering drugs) and estrogen activate a form of secretase
that destroys A[beta], says Gandy.
Miele's study shows that inhibiting gamma secretase
can block intercellular communications in cancer cells as well.
Phase 2 Study to Assess Safety, Tolerability, Pharmacokinetics of Gamma Secretase
Pratico said that their research has shown that 12/15-Lipoxygenase controls Beta secretase
(BACE-1), an enzyme that is key to the development of amyloid plaques in Alzheimer's patients.
Bristol-Myers Squibb and Chiesi presented safety and tolerably results of their gamma secretase
inhibitors, avagacestat (BMS-708163) and CHF-5074, respectively.
Over the past few years, most of the new drugs focus on an enzyme, gamma secretase
that snips a big protein to produce beta amyloid.
disease by inhibiting gamma secretase
, an enzyme that can create amyloid beta.
Furthermore, they demonstrated that Notch signalling directly stimulated survivin gene expression, and also that inhibition of the enzyme gamma secretase
(a key enzyme in the Notch signalling pathway) with GSI in ER-negative breast cancer cells abolished colony formation in soft agar and induced apoptosis.
enzymes (BACE) produce AB.
EnVivo's other clinical programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi), a Gamma Secretase
Modulator program and several preclinical programs, including a potent and selective PDE10 inhibitor program.